DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for Chronic Neutrophilic Leukemia — screening already-approved drugs against its 45-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleChronic Neutrophilic Leukemia maps to a 45-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
approvedNilotinibApproved drug
Structures already discussed alongside chronic neutrophilic leukemia in the retrieved literature, rendered from public PubChem SMILES. Which drugs appear here reflects the evidence found, not a ranked prediction.
Molecular view
Dual phosphorylated human p38 alpha — Nilotinib has a real, experimentally solved structure in complex with this target (PDB 9CJ1, 1.8 Å). This is the drug's own deposited structure, not a prediction, and confirms it is a structurally characterised molecule rather than an untested guess.
Loading structure…
helix sheet nildrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 9CJ1 · 1.8 Å · ligand Nilotinib (NIL). Experimental structure, not a prediction.
What the evidence adds up to
No abstract in the provided set addresses chronic neutrophilic leukaemia. The abstracts concern acute myeloid leukaemia and acute lymphoblastic leukaemia. In a 1996 study of 19 adults with refractory or relapsed acute leukaemia (12 ALL, 7 ANLL), salvage chemotherapy followed by G-CSF or GM-CSF produced a complete remission rate of 58% (95% CI 33% to 82%). A historical control group not receiving growth factor had a 60% complete remission rate (95% CI 44% to 77%). Growth factor accelerated neutrophil recovery to 0.5 x 10⁹/L from a mean of 28 days to 22 days (p = 0.0002), but there was no reduction in documented or fatal infections, which were high in both groups. No evidence of accelerated leukaemic regrowth was seen in the ANLL patients.
A 1993 study of GM-CSF in newly diagnosed AML patients aged 16–75 (median 50) reported a complete remission rate of 75% in the GM-CSF group versus 84% in controls. GM-CSF patients showed a trend toward more rapid blast clearance and fewer persistent leukaemias, and a significantly superior remission duration at two-and-a-half years follow-up. A 2008 phase 2 trial compared a single dose of pegfilgrastim with daily filgrastim for neutrophil recovery in low-to-intermediate risk AML; the abstract text provides only figure captions and no numerical results.
No data exist for any growth factor specifically in chronic neutrophilic leukaemia. The available evidence comes entirely from acute leukaemia populations, where growth factors shorten neutropenia but have not consistently reduced infections or improved remission rates. What is missing is any trial of G-CSF or GM-CSF in chronic neutrophilic leukaemia patients, along with the funding and patient stratification needed to determine whether neutrophil recovery benefits would translate into clinical improvement in that disease.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Leukemia & lymphoma/Leukemia and lymphoma · 1993 · 14 citations
The Role of GM-CSF in the Treatment of Acute Myeloid Leukemia
AbstractAfter a first study showed that GM-CSF following chemotherapy effectively accelerated neutrophil recovery and reduced early mortality in high risk patients with AML, a second study was begun in which GM-CSF was applied preceding chemotherapy and continuing until neutrophil recovery in the initial 5 chemotherapy courses for patients with newly diagnosed AML. The CR rate in patients of 16-75 (median 50) years was 75% in GM-CSF patients and 84% in controls. GM-CSF patients showed a trend to more frequent rapid blast clearance and fewer persistent leukemias and a significantly superior remission duration as of this update two-and-a-half years after the study started. It should be shown later by this study whether GM-CSF multiple course priming and longterm administration adds to the cure rate of patients with AML.
A Phase II Study of Nilotinib, a Novel Tyrosine Kinase Inhibitor Administered to Patients with Hypereosiniphilic Syndrome (HES).
AbstractAbstract Idiopathic hypereosinophilic syndrome (HES) is a rare myeloproliferative disorder characterized by sustained overproduction of eosinophils and organ involvement that can lead to chronic eosinophilic leukemia. HES is a clonal disorder characterized in some patients by constitutive activation of FIP1L1-PDGFRA. There is currently no approved therapy for HES. Nilotinib is a novel aminopyrimidine which potently inhibits Bcr-Abl, as well as the PDGF-R and c-Kit kinases. This Phase II study was designed to evaluate the safety and efficacy of nilotinib administered at an oral dose of 400 mg twice daily to patients with specific HES disease related criteria and with a clinical indication for treatment. Preliminary data are available for 11 patients. The median age is 63 (range 25–77) years. There were 10 males and 1 female. Extramedullary involvement was present in 6 (55%) patients at baseline. Treatment is ongoing for 4 (36%) patients and 7 (64%) have discontinued; 2 (18%) for adverse events; 3 (27%) for disease progression, and 1 (9%) for an administrative reason. There was one patient death due to neutropenic sepsis and endocarditis. Overall, 5 (45%) patients had investigator documented stable disease, and 1 (9%) patient a 51 year old male had a CR. Grade 3 or 4 adverse events included one patient each with rash, decreased hemoglobin, myalgia, arthralgia, pruritis, and diabetes mellitus. In summary, these data suggest that nilotinib has clinical activity and an acceptable safety and tolerability profile in patients with HES.
Leukemia & lymphoma/Leukemia and lymphoma · 1996 · 4 citations
Hematopoietic growth factor (G-CSF or GM-CSF) after salvage chemotherapy in refractory or relapsed adult de novo acute leukemia
AbstractNineteen adults with primary refractory or relapsed acute leukemia (12 ALL and 7 ANLL) were treated with an intensive salvage chemotherapy (intermediate-dose ara-C, intermediate-dose methotrexate, vindesine, cyclophosphamide, mitoxantrone and prednisolone) followed by a hematopoietic growth factor (HGF), either granulocyte colony-stimulating factor (5 micrograms/kg) or granulocyte-macrophage colony-stimulating factor (10 micrograms/kg). Both were given from the day after chemotherapy ended and until the neutrophil count rose above 1 X 10(9)/l for three consecutive days. Eleven patients (58%, 95% CI 33% to 82%) achieved complete remission, and 15 courses of salvage therapy were given to these complete responders. In a historical control group that did not receive HGF, 23 out of 38 patients (60%, 95% CI 44% to 77%) achieved complete remission, and 27 courses of therapy were delivered to complete responders. Treatment with a HGF accelerated the recovery of neutrophils to 0.5 X 10(9)/l significantly, shortening it from a mean of 28 to 22 days (p = .0002), with no effect on platelet recovery. There were no differences in the rates of documented and fatal infections, which were relatively high in both groups. In the patients with ANLL, there was no evidence that HGF accelerated leukemic regrowth. We conclude that HGF accelerates neutrophilic recovery following intensive salvage chemotherapy for acute leukemia, although no reduction in documented infections was found. Many factors, including the small patient sample, may have contributed to this latter finding.
Proportion of patients in complete remission overall and by subgroup
Abstract<b>Copyright information:</b>Taken from "A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial"http://www.biomedcentral.com/1471-2407/8/195BMC Cancer 2008;8():195-195.Published online 10 Jul 2008PMCID:PMC2483721.
Kaplan-Meier estimates of time to recovery from severe neutropenia in Induction 1
Abstract<b>Copyright information:</b>Taken from "A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial"http://www.biomedcentral.com/1471-2407/8/195BMC Cancer 2008;8():195-195.Published online 10 Jul 2008PMCID:PMC2483721.
Median absolute neutrophil count for pegfilgrastim and filgrastim recipients in Induction 1
Abstract<b>Copyright information:</b>Taken from "A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial"http://www.biomedcentral.com/1471-2407/8/195BMC Cancer 2008;8():195-195.Published online 10 Jul 2008PMCID:PMC2483721.
Kaplan-Meier estimates of time to recovery from severe neutropenia in Induction 1
Abstract<b>Copyright information:</b>Taken from "A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial"http://www.biomedcentral.com/1471-2407/8/195BMC Cancer 2008;8():195-195.Published online 10 Jul 2008PMCID:PMC2483721.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
